Bausch Health’s RED-C Phase 3 Trials Miss Primary Endpoint—What Does This Mean for Rifaximin in Cirrhosis Care?

RED-C Phase 3 Trials Do Not Meet Primary Target in Preventing Hepatic Encephalopathy

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) announced today that its much-anticipated RED-C Phase 3 clinical trials, evaluating amorphous-rifaximin solid soluble dispersion (SSD) in adults with liver cirrhosis, did not meet their primary endpoint. While the treatment was found safe and well-tolerated, it did not significantly delay the onset of hepatic encephalopathy (HE) in previously unaffected patients.

Large, Global Study Underscores Need for New Cirrhosis Therapies

The RED-C program enrolled more than 1,000 patients across 398 sites in 17 countries. These randomized, double-blind, placebo-controlled trials specifically targeted adults with liver cirrhosis who had not yet experienced an HE episode, with the goal of finding an effective preventive therapy where none currently exists.

Despite the neutral outcome, Bausch Health’s CEO Thomas J. Appio reaffirmed the company’s commitment to further research, highlighting the lack of approved treatments for this high-risk population. The company is reviewing the full data set to identify any new potential avenues for clinical development.

Cirrhosis Remains a Major Unmet Medical Need

Cirrhosis stands as a leading cause of end-stage liver disease in the U.S., ranking ninth as a cause of death according to recent CDC data. Progression from cirrhosis to complications such as HE, jaundice, ascites, or variceal bleeding often marks a dramatic turn in patient prognosis and quality of life.

HE represents a significant complication, and without any FDA-approved therapies for primary prevention, Bausch Health’s effort underscores both the challenge and the need for continued research and innovation.

Next Steps: Bausch Health Signals Ongoing Commitment to Hepatology Research

While the results are a setback, the company is signaling both to patients and investors its intention to fully analyze the trial data for subgroups, trends, or signals that may inspire future development. The CEO’s statement reflects both disappointment and a resolve to push forward: “We are currently reviewing the full dataset to determine potential new development opportunities.”

With ongoing programs across hepatology and broader therapeutic areas, Bausch Health’s pipeline remains active. Investors and stakeholders will be watching closely for further updates as the company digests the RED-C outcomes and recalibrates its research priorities.

Key Contacts and Additional Resources

For more detailed study information and updates about Bausch Health’s clinical pipeline, visit bauschhealth.com or the original press release.

Takeaway: Rifaximin SSD Results Remind Investors That Innovation Carries Risk

Drug development, especially in areas with high unmet medical need like hepatic encephalopathy prevention, is marked by scientific and financial risk. Bausch Health’s RED-C Phase 3 results highlight these realities, but also suggest that persistence in research may eventually yield much-needed breakthroughs.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI